TRILINEAGE RECOVERY BY COMBINATION THERAPY WITH RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR AND ERYTHROPOIETIN IN PATIENTS WITH APLASTIC-ANEMIA AND REFRACTORY-ANEMIA

被引:17
作者
BESSHO, M [1 ]
JINNAI, I [1 ]
HIRASHIMA, K [1 ]
SAITO, M [1 ]
MUROHASHI, I [1 ]
INO, H [1 ]
TSUJI, M [1 ]
FUKUDA, M [1 ]
MARUYAMA, M [1 ]
KUSUMOTO, S [1 ]
TOMINAGA, K [1 ]
MATSUDA, A [1 ]
KAWAI, N [1 ]
ITOH, K [1 ]
SAKATA, T [1 ]
HANDA, A [1 ]
ENDO, K [1 ]
TOYODA, A [1 ]
KOBAYASHI, Y [1 ]
KASHIMURA, T [1 ]
KAWANO, N [1 ]
MINAMIHISAMATSU, M [1 ]
机构
[1] NATL INST RADIOL SCI,DIV RADIAT HAZARD,CHIBA,JAPAN
关键词
APLASTIC ANEMIA; REFRACTORY ANEMIA; GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF); ERYTHROPOIETIN (EPO); MULTILINEAGE RESPONSE; TRANSFUSION;
D O I
10.1002/stem.5530120608
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Ten patients with aplastic anemia (AA) and seven patients with refractory anemia (RA) were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and erythropoietin (rhEpo) in combination. rhG-CSF (5-20 mu g/kg) and rhEpo (120-720 U/kg) were administered by s.c. injection three times a week for at least six months, and the administration was continued as maintenance therapy for as long as possible when hematological responses were observed. Six (60%) of the ten AA patients and four (58%) of the seven RA patients showed multilineage responses. Of these responders, six patients achieved trilineage recovery. While all of the responders were dependent on red blood cell transfusions and eight of them required platelet transfusions before treatment, they now no longer need transfusions of either red blood cells or platelets. A median treatment duration of 9 (range 1 to 28) months was required to achieve multilineage recovery. The responders showed an ability to maintain the multilineage recovery for 9+ to 47+ months and to tolerate long-term treatment. These results indicate that the long-term treatment with rhG-CSF and rhEpo may benefit a substantial percentage of patients with AA and RA and provide an optional therapy for these patients.
引用
收藏
页码:604 / 615
页数:12
相关论文
共 31 条
  • [1] APPELBAUM FR, 1987, BLOOD, V69, P92
  • [2] ASANO S, 1990, JPN J CLIN HEMATOL, V31, P1456
  • [3] BACIGALUPO A, 1979, NEW ENGL J MED, V300, P501
  • [4] BACIGALUPO A, 1990, BRIT J HAEMATOL, V8, P445
  • [5] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 189 - 199
  • [6] TRILINEAGE RECOVERY BY COMBINATION THERAPY WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (RHG-CSF) AND ERYTHROPOIETIN (RHEPO) IN SEVERE APLASTIC-ANEMIA
    BESSHO, M
    TOYODA, A
    ITOH, Y
    SAKATA, T
    KAWAI, N
    JINNAI, I
    SAITO, M
    HIRASHIMA, K
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (03) : 409 - 411
  • [7] IMPROVEMENT OF ANEMIA BY RECOMBINANT ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND APLASTIC-ANEMIA
    BESSHO, M
    JINNAI, I
    MATSUDA, A
    SAITO, M
    HIRASHIMA, K
    [J]. INTERNATIONAL JOURNAL OF CELL CLONING, 1990, 8 (06): : 445 - 458
  • [8] THE TREATMENT OF ANEMIA IN THE MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BOWEN, D
    CULLIGAN, D
    JACOBS, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) : 419 - 423
  • [9] CAMITTA BM, 1979, BLOOD, V53, P504
  • [10] CAMITTA BM, 1982, NEW ENGL J MED, V306, P645